Literature DB >> 7664176

Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine.

V Bonnevie-Nielsen1, I Heron, T P Monath, C H Calisher.   

Abstract

Primary and secondary immunizations with live, attenuated yellow fever virus vaccine (17D strain) were performed in order to study the course of appearance of virus-neutralizing antibodies and immunoglobulin M (IgM) and IgG antibodies directed against the virus and the interferon-dependent enzyme 2',5'-oligoadenylate synthetase (2',5'AS) activity, determined in homogenates of peripheral B and T lymphocytes. From cellular ATP, this enzyme generates 2',5'-oligoadenylates which mediate degradation of viral mRNA by stimulation of a latent RNase. By day 4 after the first immunization, the earliest and highest 2',5'AS activity was present in the T-lymphocyte fraction. By day 7, the enzyme activity was highest in the B-lymphocyte fraction. Virus-neutralizing antibodies appeared on day 7, and IgM antibodies were present on day 12. After the second immunization, performed 2 years +/- 2 months later, the only significant increase in 2',5'AS activity was observed in the T-lymphocyte fraction. Virus-neutralizing antibodies were present from day 1, whereas no IgM antibodies were detected. By day 12, 80% of the vaccines were IgG positive. In the primary and secondary (memory) immune responses, 2',5'AS activity is expressed in the T-lymphocyte fraction prior to the appearance of antibodies directed against the virus and may serve as an early and sensitive marker of an ongoing virus infection which is otherwise difficult to detect. No change in conventional laboratory analysis parameters, such as in differential blood cell counts or total IgA, IgG, and IgM, disclosed the immune activity in either the primary or the secondary immunization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664176      PMCID: PMC170150          DOI: 10.1128/cdli.2.3.302-306.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  39 in total

Review 1.  Antiviral activity of interferons.

Authors:  R M Friedman
Journal:  Bacteriol Rev       Date:  1977-09

2.  Simplified procedure for the separation of human T and non-T cells.

Authors:  F Gmelig-Meyling; R E Ballieux
Journal:  Vox Sang       Date:  1977-07       Impact factor: 2.144

3.  Interferons, double-stranded RNA, and RNA degradation. Isolation and characterization of homogeneous human (2'-5')(a)n synthetase.

Authors:  K Yang; H Samanta; J Dougherty; B Jayaram; R Broeze; P Lengyel
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

4.  Mechanisms of killing of measles virus-infected cells by human lymphocytes: interferon associated and unassociated cell-mediated cytotoxicity.

Authors:  P Casali; M B Oldstone
Journal:  Cell Immunol       Date:  1982-07-01       Impact factor: 4.868

5.  Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis.

Authors:  T P Monath; R R Nystrom; R E Bailey; C H Calisher; D J Muth
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

6.  Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells.

Authors:  D Wallach; M Fellous; M Revel
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

7.  Interferon-induced 2-5A synthetase activity in human peripheral blood mononuclear cells after immunization with influenza virus and rubella virus vaccines.

Authors:  L J Penn; B R Williams
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Variation of (2'-5') oligo A synthetase level in lymphocytes and granulocytes of patients with viral infections and leukemia.

Authors:  A Schattner; D Wallach; G Merlin; T Hahn; S Levin; B Ramot; M Revel
Journal:  J Interferon Res       Date:  1982

9.  Elongation mechanism and substrate specificity of 2',5'-oligoadenylate synthetase.

Authors:  J Justesen; D Ferbus; M N Thang
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

Review 10.  Natural killer cells: their roles in defenses against disease.

Authors:  R B Herberman; J R Ortaldo
Journal:  Science       Date:  1981-10-02       Impact factor: 47.728

View more
  7 in total

1.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

Review 2.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

Review 3.  Yellow fever: a reemerging threat.

Authors:  Christina L Gardner; Kate D Ryman
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

4.  A live, attenuated recombinant West Nile virus vaccine.

Authors:  Thomas P Monath; Jian Liu; Niranjan Kanesa-Thasan; Gwendolyn A Myers; Richard Nichols; Alison Deary; Karen McCarthy; Casey Johnson; Thomas Ermak; Sunheang Shin; Juan Arroyo; Farshad Guirakhoo; Jeffrey S Kennedy; Francis A Ennis; Sharone Green; Philip Bedford
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

5.  Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Authors:  Anabelle Lefeuvre; Philippe Marianneau; Vincent Deubel
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

Review 6.  Pathogenesis of flavivirus encephalitis.

Authors:  Thomas J Chambers; Michael S Diamond
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

7.  Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.

Authors:  Jon L Belsher; Peter Gay; Margo Brinton; Joseph DellaValla; Robert Ridenour; Robert Lanciotti; Andrey Perelygin; Sherif Zaki; Christopher Paddock; Troy Querec; Tuofu Zhu; Bali Pulendran; Rachel B Eidex; Edward Hayes
Journal:  Vaccine       Date:  2007-09-18       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.